Literature DB >> 21596859

A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia.

Yaoyu Chen1, Con Sullivan, Cong Peng, Yi Shan, Yiguo Hu, Dongguang Li, Shaoguang Li.   

Abstract

We have shown that Alox5 is a critical regulator of leukemia stem cells (LSCs) in a BCR-ABL-induced chronic myeloid leukemia (CML) mouse model, and we hypothesize that the Alox5 pathway represents a major molecular network that regulates LSC function. Therefore, we sought to dissect this pathway by comparing the gene expression profiles of wild type and Alox5(-/-) LSCs. DNA microarray analysis revealed a small group of candidate genes that exhibited changes in the levels of transcription in the absence of Alox5 expression. In particular, we noted that the expression of the Msr1 gene was upregulated in Alox5(-/-) LSCs, suggesting that Msr1 suppresses the proliferation of LSCs. Using CML mouse model, we show that Msr1 is downregulated by BCR-ABL and this down-regulation is partially restored by Alox5 deletion, and that Msr1 deletion causes acceleration of CML development. Moreover, Msr1 deletion markedly increases LSC function through its effects on cell cycle progression and apoptosis. We also show that Msr1 affects CML development by regulating the PI3K-AKT pathway and β-Catenin. Together, these results demonstrate that Msr1 suppresses LSCs and CML development. The enhancement of the tumor suppressor function of Msr1 may be of significance in the development of novel therapeutic strategies for CML.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596859      PMCID: PMC3138690          DOI: 10.1182/blood-2010-11-316760

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  Diverse mechanisms regulate stem cell self-renewal.

Authors:  Anna V Molofsky; Ricardo Pardal; Sean J Morrison
Journal:  Curr Opin Cell Biol       Date:  2004-12       Impact factor: 8.382

2.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Authors:  Paolo Neviani; Ramasamy Santhanam; Rossana Trotta; Mario Notari; Bradley W Blaser; Shujun Liu; Hsiaoyin Mao; Ji Suk Chang; Annamaria Galietta; Ashwin Uttam; Denis C Roy; Mauro Valtieri; Rebecca Bruner-Klisovic; Michael A Caligiuri; Clara D Bloomfield; Guido Marcucci; Danilo Perrotti
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

3.  Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways.

Authors:  Anna V Molofsky; Shenghui He; Mohammad Bydon; Sean J Morrison; Ricardo Pardal
Journal:  Genes Dev       Date:  2005-06-15       Impact factor: 11.361

4.  kat: a high-efficiency retroviral transduction system for primary human T lymphocytes.

Authors:  M H Finer; T J Dull; L Qin; D Farson; M R Roberts
Journal:  Blood       Date:  1994-01-01       Impact factor: 22.113

5.  Transcriptional inhibition by interleukin-6 of the class A macrophage scavenger receptor in macrophages derived from human peripheral monocytes and the THP-1 monocytic cell line.

Authors:  H S Liao; A Matsumoto; H Itakura; T Doi; M Honda; T Kodama; Y J Geng
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-08       Impact factor: 8.311

6.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.

Authors:  Omer H Yilmaz; Riccardo Valdez; Brian K Theisen; Wei Guo; David O Ferguson; Hong Wu; Sean J Morrison
Journal:  Nature       Date:  2006-04-05       Impact factor: 49.962

7.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Authors:  Hans-Guido Wendel; Elisa de Stanchina; Enriqué Cepero; Sagarika Ray; Michael Emig; Jordan S Fridman; Darren R Veach; William G Bornmann; Bayard Clarkson; W Richard McCombie; Scott C Kogan; Andreas Hochhaus; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

8.  Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene.

Authors:  X S Chen; J R Sheller; E N Johnson; C D Funk
Journal:  Nature       Date:  1994-11-10       Impact factor: 49.962

9.  Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Authors:  Yiguo Hu; Sarah Swerdlow; Theodore M Duffy; Roberto Weinmann; Francis Y Lee; Shaoguang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

10.  FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress.

Authors:  Zuzana Tothova; Ramya Kollipara; Brian J Huntly; Benjamin H Lee; Diego H Castrillon; Dana E Cullen; Elizabeth P McDowell; Suzan Lazo-Kallanian; Ifor R Williams; Christopher Sears; Scott A Armstrong; Emmanuelle Passegué; Ronald A DePinho; D Gary Gilliland
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

View more
  14 in total

Review 1.  Targeting survival pathways in chronic myeloid leukaemia stem cells.

Authors:  A Sinclair; A L Latif; T L Holyoake
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

2.  Novel subtypes of NPM1-mutated AML with distinct outcome.

Authors:  Arvind Singh Mer; Mark D Minden; Benjamin Haibe-Kains; Aaron D Schimmer
Journal:  Mol Cell Oncol       Date:  2021-06-30

3.  Network-based survival analysis to discover target genes for developing cancer immunotherapies and predicting patient survival.

Authors:  Xinwei He; Xiaoqiang Sun; Yongzhao Shao
Journal:  J Appl Stat       Date:  2020-09-03       Impact factor: 1.416

Review 4.  Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.

Authors:  Xiaofei Yu; Chunqing Guo; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2015-06-17       Impact factor: 6.242

Review 5.  Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks.

Authors:  Francesca Pellicano; Tessa L Holyoake
Journal:  J Exp Med       Date:  2011-10-24       Impact factor: 14.307

Review 6.  Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.

Authors:  Andreas Burchert
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

7.  Molecular signatures of chronic myeloid leukemia stem cells.

Authors:  Yaoyu Chen; Shaoguang Li
Journal:  Biomark Res       Date:  2013-06-06

8.  The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.

Authors:  Yi Ru; Qinhao Wang; Xiping Liu; Mei Zhang; Daixing Zhong; Mingxiang Ye; Yuanchun Li; Hua Han; Libo Yao; Xia Li
Journal:  Sci Rep       Date:  2016-06-22       Impact factor: 4.379

9.  Mtss1 is a critical epigenetically regulated tumor suppressor in CML.

Authors:  M Schemionek; O Herrmann; M M Reher; N Chatain; C Schubert; I G Costa; S Hänzelmann; E G Gusmao; S Kintsler; T Braunschweig; A Hamilton; G V Helgason; M Copland; A Schwab; C Müller-Tidow; S Li; T L Holyoake; T H Brümmendorf; S Koschmieder
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

10.  MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples.

Authors:  Vladimir Trifonov; Laura Pasqualucci; Riccardo Dalla Favera; Raul Rabadan
Journal:  BMC Syst Biol       Date:  2013-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.